Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles

CHEN Dazhong; GAO Jie; XIE Fangyuan; ZHANG He; LU Ying; ZOU Hao; ZHONG Yanqiang

doi:10.3969/j.issn.1006-0111.2017.03.007

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To establish methods for the determination of doxorubicin and elacridar, and prepare PLGA nanoparticles for the co-delivery of doxorubicin and elacridar. Methods Ultraviolet spectrophotometry (UV) and high performance liquid chromatography (HPLC) were used to establish the determination method of doxorubicin and elacridar, respectively; co-delivery nanoparticles system was prepared by nanoprecipitation method, and optimizing the prescription was by adjusting the dosage ratio of the two drugs to investigate the particle size,morphology, encapsulation efficiency (EE), drug loading (DL) and in vitro release. Results The linearity of doxorubicin was better in the rang of 1 to 40 μg/ml, A=0.021C+0.002,r=0.999 5;the linearity of elacridar was better in the rang of 0.5 to 100 μg/ml,A=120 742.462 6C+1 974.570 4,r=1.000 0;the particle size was about 50 nm; transmission electron microscope (TEM) showed that nanoparticles were round in shape and had a good dispersion;EE of doxorubicin and elacridar were 56.58%、51.66%,respectively, DL of doxorubicin and elacridar were 1.48%、1.85%,respectively,the molar ratio of two drugs was about 1:1;the nanoparticles released slowly in vitro. Conclusion The established methods of doxorubicin and elacridar were convenient and efficient, accurate and repeatable.The Co-delivery nanoparticles system was well dispersionand smaller size, which could be used for further studies.

Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles

School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2017-01-18

Rev Recd Date: 2017-03-31

Key words:

doxorubicin /
elacridar /
nanoparticles /
UV /
HPLC

Abstract: Objective To establish methods for the determination of doxorubicin and elacridar, and prepare PLGA nanoparticles for the co-delivery of doxorubicin and elacridar. Methods Ultraviolet spectrophotometry (UV) and high performance liquid chromatography (HPLC) were used to establish the determination method of doxorubicin and elacridar, respectively; co-delivery nanoparticles system was prepared by nanoprecipitation method, and optimizing the prescription was by adjusting the dosage ratio of the two drugs to investigate the particle size,morphology, encapsulation efficiency (EE), drug loading (DL) and in vitro release. Results The linearity of doxorubicin was better in the rang of 1 to 40 μg/ml, A=0.021C+0.002,r=0.999 5;the linearity of elacridar was better in the rang of 0.5 to 100 μg/ml,A=120 742.462 6C+1 974.570 4,r=1.000 0;the particle size was about 50 nm; transmission electron microscope (TEM) showed that nanoparticles were round in shape and had a good dispersion;EE of doxorubicin and elacridar were 56.58%、51.66%,respectively, DL of doxorubicin and elacridar were 1.48%、1.85%,respectively,the molar ratio of two drugs was about 1:1;the nanoparticles released slowly in vitro. Conclusion The established methods of doxorubicin and elacridar were convenient and efficient, accurate and repeatable.The Co-delivery nanoparticles system was well dispersionand smaller size, which could be used for further studies.

HTML

Reference (11)

[1]	Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells[J]. Nature, 2001,414(6859):105-111.
[2]	Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening[J]. Cell, 2009, 138(4):645-659.
[3]	Cojoc M, Mäbert K, Muders MH, et al. A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms[J]. Semin Cancer Biol, 2014, 31:16-27.
[4]	Hubensack M, Müller C, Höcherl P, et al. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice[J]. J Cancer Res Clin Oncol, 2008, 134(5): 597-607.
[5]	Karla PK, Earla R, Boddu SH, et al. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells[J]. Curr Eye Res, 2009, 34(1): 1-9.
[6]	Nieto Montesinos RM, Beduneau A, Lamprecht A, et al. Liposomes co-loaded with elacridar and tariquidar to modulate the P-glycoprotein at the blood-brain barrier[J]. Mol Pharm, 2015, 12(11):3829-3838.
[7]	Wong HL, Bendayan R, Rauth AM, et al. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer[J]. J Control Release, 2006, 116(3):275-284.
[8]	Singh MS, Lamprecht A. Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin[J]. Int J Pharm, 2015, 478(2):745-752.
[9]	Planting AST,Sonneveld P,Gaast AVD,et al.A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors[J].Cancer Chemother Pharmacol,2005,55(1):91-99.
[10]	Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery[J]. Biomaterials, 2007, 28(5):869-876.
[11]	Zhu H, Chen H, Zeng X, et al. Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance[J]. Biomaterials, 2013, 35(7):2391-2400.

Message Board

Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles

doi: 10.3969/j.issn.1006-0111.2017.03.007

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views